Effects of plasmid-based Stat3-specific short hairpin RNA and GRIM-19 on PC-3M tumor cell growth

Clinical Cancer Research

Volumn 14, Issue 2, 2008, Pages 559-568

  Zhang, Ling ^a   Gao, Lifang ^a   Li, Yang ^a   Lin, Guimiao ^a   Shao, Yueting ^a   Ji, Kun ^a   Yu, Hao ^a   Hu, Jiadi ^b   Kalvakolanu, Dhananjaya V ^b   Kopecko, Dennis J ^c   Zhao, Xuejian ^a   Xu, De Qi ^c  

^a JILIN UNIVERSITY   (China)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GRIM 19 PROTEIN; INHIBITOR PROTEIN; INTERFERON; PLASMID VECTOR; SHORT HAIRPIN RNA; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; GENE REPRESSION; GENE SEQUENCE; GENE TARGETING; GENETIC CODE; HUMAN; HUMAN CELL; IN VIVO STUDY; MALE; METASTASIS; MORTALITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROSTATE TUMOR; PROTEIN TARGETING; RNA INTERFERENCE; TUMOR CELL; TUMOR GROWTH;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; NADH, NADPH OXIDOREDUCTASES; PLASMIDS; PROSTATE; PROSTATIC NEOPLASMS; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION, GENETIC; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 38949088674     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1176     Document Type: Article

References (43)

1. Pisani P, Parkin DM, Bray F, Ferlay J. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
2. Nicholson B, Theodorescu D. Molecular therapeutics in prostate cancer. Histol Histopathol 2003;18:275-98.
3. Mora LB, Buettner R, Seigne J, et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res 2002;62:6659-66.
4. Darnell JE, Jr. STATs and gene regulation. Science 1997;277:1630-5.
5. Lu Y, Fukuyama S, Yoshida R, et al. Loss of SOCS3 gene expression converts STAT3 function from antiapoptotic to pro-apoptotic. J Biol Chem 2006;281:36683-90.
6. Catlett-Falcone R, Dalton WS, Jove R. STAT proteins as novel targets for cancer therapy. Signal transducer an activator of transcription. Curr Opin Oncol 1999;11:490-6.
7. Turkson J. STAT proteins as novel targets for cancer drug discovery. Expert Opin Ther Targets 2004;8:409-22.
8. Masuda M, Suzui M, Yasumatu R, et al. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res 2002;62:3351-5.
9. Bromberg JF, Wrzeszczynska MH, Devgan G, et al. Stat3 as an oncogene. Cell 1999;98:295-303.
10. Ala S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. Cancer Res 2001;61:5137-44.
11. Puthier D, Bataille R, Amiot M. IL-6 up-regulates mcl-1 in human myeloma Cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 1999;29:3945-50.
12. Aoki Y, Feldman GM, Tosato G. Inhibition of STAT3 signaling induces apoptosis and decreases surviving expression in primary effusion lymphoma. Blood 2003;101:1535-42.
13. Niu G, Wright KL, Huang M, et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 2002;21:2000-8.
14. Wei D, Le X, Zheng L, et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 2003;22:319-29.
15. Xie TX, Wei D, Liu M, et al. Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis. Oncogene 2004;23:3550-60.
16. Leong PL, Adrews GA, Johnson DE, et al. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc Natl Acad Sci U S A 2003;100:4138-43.
17. Lee SO, Lou W, Khusroo M, Mehraein-Ghomi F, Trump DL, Gao AC. RNA interference targeting Stat3 inhibits growth and induces apoptosis of human prostate cancer cells. Prostate 2004;60:303-9.
18. Ling X, Arlinghaus RB. Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res 2005;65:2532-6.
19. Gao L, Zhang L, Hu J, et al. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin Cancer Res 2005;11:6333-41.
20. Hannon GJ. RNA interference. Nature 2002;418:244-51.
21. Tuschl T, Borkhard A. Small interfering RNAs: a revolutionary tool for the analysis of gene function and gene therapy. Mol Interv 2002;2:158-67.
22. Paddison PJ, Caudy AA, Bernstein E, Hannon J, Conklin DS. Short hairpin RNAs (shRNAs) induce sequence-specific silencing in mammalian cells. Genes Dev 2002;16:948-58.
23. Elbashir SM, Harborth J, Weber K, Tuschl T. Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods 2002;26:199-213.
24. Angell JE, Lindner DJ, Shapiro PS, Hofmann ER, Kalvakolanu DV. Identification of GRIM-19, a novel cell death-regulatory gene induced by the interferon-β and retinoic acid combination, using a genetic approach. J Biol Chem 2000;275:33416-26.
25. Zhang J, Yang J, Roy SK, et al. The cell death regulator GRIM-19 is an inhibitor of signal transducer and activator of transcription 3. Proc Natl Acad Sci U S A 2003;100:9342-7.
26. Lufei C, Ma J, Huang G, et al. GRIM-19, a death-regulatory gene product, suppresses Stat3 activity via functional interaction. EMBO J 2003;22:1325-35.
27. Maximo V, Botelho T, Capela J, et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hûrthle cell) tumours of the thyroid. Br J Cancer 2005;92:1892-8.
28. Alchanati I, Nalla SC, Sun P, et al. A proteomic analysis reveals the loss of expression of the cell death regulatory gene GRIM-19 in human renal cell carcinomas. Oncogene 2006;25:7138-47.
29. Hu J, Angell JE, Zhang J, et al. Characterization of monoclonal antibodies against GRIM-19, a novel IFN-β and retinoic acid-activated regulator of cell death. J Interferon Cytokine Res 2002;22:1017-26.
30. Steinman RA, Wentzel A, Lu Y, Stehle C, Grandis JR. Activation of Stat3 by cell confluence reveals negative regulation of Stat3 by cdk2. Oncogene 2003;22:3608-15.
31. Lalu MM, Csonka C, Giricz Z, et al. Estimates of the worldwide mortality from 25 cancers in 1990. Int J Cancer 1999;83:18-29.
32. Buettner R, Mora LB, Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin Cancer Res 2002;8:945-54.
33. Gerdes J, Li L, Schlueter C, et al. Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67. Am J Pathol 1991;38:867-73.
34. Yang J, Chatterjee-Kishore M, Staugaitis SM, et al. Novel roles of unphosphorylated STAT3 in oncogenesis and transcriptional regulation. Cancer Res 2005;65:939-47.
35. Zhang X, Huang Q, Yang Z, Li Y, Li CY. GW112, a novel antiapoptotic protein that promotes tumor growth. Cancer Res 2004;64:2474-81.
36. Real PJ, Sierra A, De Juan A, Segovia JC, Lopez-Vega JM, Fernandez-Luna JL. Resistance to chemotherapy via Stat3-dependent overexpression of Bcl-2 in metastatic breast cancer cells. Oncogene 2002;21:7611-8.
37. Suiqing C, Min Z, Lirong C. Overexpression of phosphorylated-STAT3 correlated with the invasion and metastasis of cutaneous squamous cell carcinoma. J Dermatol 2005;32:354-60.
38. Cemazar M, Golzio M, Sersa G, Rols MP, Teissie J. Electrically-assisted nucleic acids delivery to tissues in vivo : where do we stand [review]? Curr Pharm Des 2006;12:3817-25.
39. Mir LM, Bureau MF, Gehl J, et al. High-efficiency gene transfer into skeletal musle mediated by electric pulses. Proc Natl Acad Sci U S A 1999;96:4262-7.
40. Rols MP, Delteil C, Golzio M, Dumond P, Cros S, Teissie J. iiiIn vivo electrically mediated protein and gene transfer in murine melanoma. Nat Biotechnol 1998;16:168-71.
41. Gothelf A, Mir LM, Gehl J. Electrochmotherapy: results of cancer treatment using enhanced delivery of bleomycin by electroporation. Cancer Treat Rev 2003;29:371-87.
42. Nishi T, Yoshizato K, Yamashiro S, et al. High-efficiency in vivo gene transfer using in-traarterial plasmid DNA injection following in vivo electroporation. Cancer Res 1996;56:1050-5.
43. Zhang L, Gao L, Guo B, et al. Intratumoral delivery and suppression of prostate tumor growth by attenuated Salmonella enterica serovar typhimurium carrying plasmid-based siRNAs. Cancer Res 2007;67:5859-64.